Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
50.95
Nov 20 • 3:59 PM ET Dollar change-1.58 Percentage change(-3.01%)
Aftermarket Close
50.95
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Category
US Equities - Industry Sector
Sponsor
ALPS
Fund Family
Index
S-Network Medical Breakthroughs Index
Index Weighting
Active/Passive
Expense
0.50%
Inverse/Leveraged
IPO
Dec 31, 2014
Asset Type
Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short
Yes / Yes
Tags
Tags
Tags
Tags
Tags
Tags
Tags
Sector/Theme
Region
SMA20
-7.13%
SMA50
-9.10%
SMA200
-11.01%
Return% 1Y
9.36%
Return% 3Y
27.96%
Return% 5Y
2.65%
Return% 10Y
Return% SI
Flows% 1M
-3.13%
Flows% 3M
-1.65%
Flows% YTD
49.84%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades
Total Holdings
104
AUM
170.88M
NAV/sh
52W High
70.85 -28.09%
52W Low
45.65 11.61%
Volatility
3.54% 3.22%
ATR (14)
1.83
RSI (14)
36.50
Beta
0.79
Rel Volume
1.74
Avg Volume
35.78K
Volume
62,263
Perf Week
-8.42%
Perf Month
-6.60%
Perf Quarter
-25.77%
Perf Half Y
-4.41%
Perf YTD
-0.53%
Perf Year
10.57%
Perf 3Y
98.96%
Perf 5Y
13.29%
Perf 10Y
97.79%
Prev Close
52.53
Price
50.95
Change %
-3.01%
ALPS Medical Breakthroughs ETF seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.